Novavax Identified an "Ideal" Coronavirus Vaccine Candidate
The news from Novavax (NVAX) informs that the firm has identified an "ideal" coronavirus vaccine candidate, NVX-CoV2373, that is a stable, prefusion protein made using Novavax’s proprietary nanoparticle technology. The firm will initiate a first-in-human trial in mid-May.
Novavax’s proprietary Matrix-M . . .
This content is for paid subscribers.
Impacting News
April 8, 2020
